Trusted by:
A neurosurgeon at the Methodist Neurological Institute (NI) found a new way to label nanotubes using quantum dots, a discovery that could give researchers a new view into cancer cells, proteins, and DNA molecules.
A five-year follow-up study finds that a combination of radiation and suicide gene therapy is eliminating the spread of prostate cancer and providing a long term vaccine against the disease.
Research conducted at the Methodist DeBakey Heart Center in Houston shows a 70 percent reduction in LDL-c, or bad cholesterol, using a combination therapy of two statin drugs. This is the largest reduction in bad cholesterol ever seen in a statin clinical trial.
Research conducted at the Methodist DeBakey Heart Center in Houston shows that a combination statin therapy already proven to lower bad cholesterol by a dramatic 70 percent, now has the added benefit of reducing life-threatening inflammation that can lead to heart disease.
Research conducted by retina surgeons at The Methodist Hospital shows unprecedented improvements in vision in more than one-third of patients treated with Lucentisâ„¢ for wet age-related macular degeneration (AMD), according to findings published in the New England Journal of Medicine.
A novel toxin resembling a snake venom poison contributes to severe group A Streptococcus "flesh-eating" infections. This discovery provides promise for the development of new therapies to treat some forms of these life-threatening infections.
The immune cells of the spinal cord and brain contribute significantly to prolonging survival in a model of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that results in paralysis and eventual death, according to a study published today in Proceedings of the National Academy of Sciences U.S.A.
This is a study involving obesity and inflammation that could lead to new therapies to prevent diabetes and heart disease.
Data presented indicates effectiveness of new treatment for kidney transplant recipients.
Research published today shows that a combination statin therapy lowers bad cholesterol by an unprecedented 70 percent, and has the added benefit of reducing life-threatening inflammation that can lead to heart disease and stroke. This is the biggest drop in bad cholesterol ever seen in a statin clinical trial.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right